Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg hikes target price on Coats following H1 numbers

(Sharecast News) - Analysts at Berenberg raised their target price on thread and structural components manufacturer Coats Group from 100.0p to 120.0p on Friday as it said the group was "knitting it all together" during H1. Berenberg said Coats' interim results for the six months to 30 June showed "a highly credible organic growth performance" and noted that a slight upgrade to FY24 guidance, stronger-than-expected margin performance and incrementally more positive commentary about the market recovery saw the shares react strongly on the day after having been range-bound for the past few years.

"At a current valuation of 12.5x FY25 P/E, we still see a lot to like in the shares. We move our price target to 120p (from 100p) as the group enters into what we expect could be the start of a sustained market recovery and upgrade cycle," said Berenberg, which stood by its 'buy' recommendation on the stock.

"We roll our previous valuation methodology of 15x FY1 P/E over from our FY24 forecasts to our FY25 forecasts. Beyond mechanics, we also think it is logical to assign more value to Coats on the back of its H1 results: organic growth has continued to build, with all three divisions in growth in Q2, and this is expected to continue; margins of 18% were provably ahead of management's FY24 target; and volumes and destocking trends have continued to normalise into what now looks like a sustainable market recovery."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Smith & Nephew appoints Ajay Dhankhar as chief corporate development & strategy officer
(Sharecast News) - Medical technology company Smith & Nephew said on Monday that it has appointed Ajay Dhankhar as chief corporate development & strategy officer with immediate effect.
Oxford Biomedica acquires last 10pc stake in US subsidiary
(Sharecast News) - Oxford Biomedica said on Monday it has acquired the remaining 10% stake in its US subsidiary, OXB US, from Q32 Bio, bringing its ownership of the business to 100% as previously planned.
PPHE acquiring prime London site for hotel development
(Sharecast News) - PPHE Hotel Group has announced the acquisition of a prime development site near the City of London, where it plans to build its first Radisson RED select service hotel in the capital.
Norcros to end tile production in South Africa
(Sharecast News) - Norcros announced on Monday that it will shut down manufacturing at Johnson Tiles South Africa at the end of June, following the conclusion of a strategic review.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.